PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16243513-16 2005 Eliminating the effect on mortality of higher stage and grade of the clinical prostate cancer and PSA at baseline, the following statistically significant correlations remained: a higher fasting plasma insulin level (P = 0.010) and a lower HDL-cholesterol level of borderline significance (P = 0.065). Cholesterol 244-255 kallikrein related peptidase 3 Homo sapiens 98-101 18957682-5 2008 The association between change in PSA and change in cholesterol parameters (low-density lipoprotein [LDL], high-density lipoprotein [HDL], and total cholesterol) was analyzed using multivariate linear regression. Cholesterol 52-63 kallikrein related peptidase 3 Homo sapiens 34-37 16752375-8 2006 However, adjustment for prior high blood pressure or high cholesterol diagnoses reduced the BMI-PSA testing associations. Cholesterol 58-69 kallikrein related peptidase 3 Homo sapiens 96-99 12474543-2 2002 OBJECTIVE: To assess the relationship between health risk indicators (e.g., cholesterol, blood pressure, blood sugar, and percent body fat), which are related to dietary fat intake, and prostate-specific antigen (PSA) scores. Cholesterol 76-87 kallikrein related peptidase 3 Homo sapiens 186-217 11125428-10 2001 CONCLUSIONS: This study reveals that short-term exposure of elderly men with elevated serum PSA values to soy protein containing isoflavones decreases serum cholesterol but not the serum biomarkers PSA and p105erbB-2. Cholesterol 157-168 kallikrein related peptidase 3 Homo sapiens 92-95 35067054-4 2022 When prostate specific antigen (PSA) taken as a model analyte was introduced into the suspension of MMNP, PSA cleaved the amide bond of SK in cholesterol-(CH2)6-HSSKLQK-Fc, and then the cleaved peptide-motif-Fc-quencher was deviated from the MMNP, resulting in the increase in the ECL intensity. Cholesterol 142-153 kallikrein related peptidase 3 Homo sapiens 5-30 35067054-4 2022 When prostate specific antigen (PSA) taken as a model analyte was introduced into the suspension of MMNP, PSA cleaved the amide bond of SK in cholesterol-(CH2)6-HSSKLQK-Fc, and then the cleaved peptide-motif-Fc-quencher was deviated from the MMNP, resulting in the increase in the ECL intensity. Cholesterol 142-153 kallikrein related peptidase 3 Homo sapiens 32-35 35067054-4 2022 When prostate specific antigen (PSA) taken as a model analyte was introduced into the suspension of MMNP, PSA cleaved the amide bond of SK in cholesterol-(CH2)6-HSSKLQK-Fc, and then the cleaved peptide-motif-Fc-quencher was deviated from the MMNP, resulting in the increase in the ECL intensity. Cholesterol 142-153 kallikrein related peptidase 3 Homo sapiens 106-109 34817559-2 2022 Prostate-specific antigen levels are affected by use of cholesterol-lowering statin drugs, but the association of statin use with PSA screening performance is unknown. Cholesterol 56-67 kallikrein related peptidase 3 Homo sapiens 0-25 31752806-5 2019 RESULTS: When simultaneously adjusting for age, BMI, prostate volume and high-density lipoprotein cholesterol, serum insulin levels and SHBG levels were inversely correlated with serum PSA levels (P = 0.049 and P = 0.004, respectively), and testosterone levels were positively correlated with serum PSA levels (P = 0.039). Cholesterol 98-109 kallikrein related peptidase 3 Homo sapiens 185-188 30079314-7 2018 PSA, a biomarker of prostate cancer, was significantly and positively correlated with the intake of animal iron and cholesterol in men. Cholesterol 116-127 kallikrein related peptidase 3 Homo sapiens 0-3 24938184-11 2014 Positive associations were observed between PSA testing and more chronic illnesses (OR=1.11, 95% CI 1.05-1.19), more primary care visits (OR=1.03, 95% CI 1.01-1.05) and preventative health practices, including cholesterol testing and influenza vaccination (OR=1.35, 95% CI 1.13-1.60). Cholesterol 210-221 kallikrein related peptidase 3 Homo sapiens 44-47 29282360-2 2018 Prostate-specific antigen (PSA) is positively correlated with cholesterol, potentially increasing PSA-driven biopsy recommendations in men with high cholesterol, though biopsy compliance may be lower in men with comorbid conditions. Cholesterol 62-73 kallikrein related peptidase 3 Homo sapiens 0-31 29282360-2 2018 Prostate-specific antigen (PSA) is positively correlated with cholesterol, potentially increasing PSA-driven biopsy recommendations in men with high cholesterol, though biopsy compliance may be lower in men with comorbid conditions. Cholesterol 62-73 kallikrein related peptidase 3 Homo sapiens 27-30 29282360-2 2018 Prostate-specific antigen (PSA) is positively correlated with cholesterol, potentially increasing PSA-driven biopsy recommendations in men with high cholesterol, though biopsy compliance may be lower in men with comorbid conditions. Cholesterol 149-160 kallikrein related peptidase 3 Homo sapiens 0-31 29282360-2 2018 Prostate-specific antigen (PSA) is positively correlated with cholesterol, potentially increasing PSA-driven biopsy recommendations in men with high cholesterol, though biopsy compliance may be lower in men with comorbid conditions. Cholesterol 149-160 kallikrein related peptidase 3 Homo sapiens 27-30 29282360-3 2018 These potential biases may affect PSA-driven biopsy rates and subsequent prostate cancer detection in men with high serum cholesterol. Cholesterol 122-133 kallikrein related peptidase 3 Homo sapiens 34-37 29282360-4 2018 Our objective was to test the association between serum cholesterol and prostate cancer risk in men receiving PSA independent, study-mandated prostate biopsies. Cholesterol 56-67 kallikrein related peptidase 3 Homo sapiens 110-113 25723617-8 2015 In addition, multivariable linear regression analysis demonstrated that PSA was positively correlated with age, total cholesterol (TC) and preDM (p < 0.05). Cholesterol 118-129 kallikrein related peptidase 3 Homo sapiens 72-75 22292623-7 2011 The mean value of total cholesterol levels (237.9 +- 31.2 mg/dl) was also increased along with raised PSA levels in cases when compared with controls (184 +- 33.8 mg/dl) (p=0.0001). Cholesterol 24-35 kallikrein related peptidase 3 Homo sapiens 102-105 20073066-7 2010 Serum prostate-specific antigen (PSA) level was compared between current users and non-users of cholesterol-lowering drugs. Cholesterol 96-107 kallikrein related peptidase 3 Homo sapiens 6-37 20073066-11 2010 Age-adjusted median serum PSA tended to be lower among users of cholesterol-lowering drugs, but the relative risk decrease among statin users was not related to decreased PSA. Cholesterol 64-75 kallikrein related peptidase 3 Homo sapiens 26-29 20072809-1 2010 PURPOSE: We evaluated the associations of statins and serum cholesterol with PSA to understand whether the inverse associations of statins and low cholesterol with aggressive prostate cancer are explained by detection bias. Cholesterol 60-71 kallikrein related peptidase 3 Homo sapiens 77-80 20072809-7 2010 Men with lower cholesterol had lower PSA (bottom vs. top quintile: 0.92, 1.02 ng/mL, p-trend = 0.06). Cholesterol 15-26 kallikrein related peptidase 3 Homo sapiens 37-40 20072809-8 2010 CONCLUSION: Statin users and men with lower cholesterol may have lower PSA. Cholesterol 44-55 kallikrein related peptidase 3 Homo sapiens 71-74